LISATA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
LISATA THERAPEUTICS, INC. (LSTA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.97 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.97, a 48.16% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.80, a 23.78% increase year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.07, a 1.29% decline year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.11, a 241.76% increase year-over-year.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.80, a 23.78% increase from fiscal 2024.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.07, a 11.01% decline from fiscal 2023.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.45, a 74.43% decline from fiscal 2022.
- LISATA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $13.49, a 921.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.97 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.97 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $3.80 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $3.80 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $3.80 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $3.80 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $3.07 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $3.07 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $3.07 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $3.07 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $3.45 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $3.46 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $3.50 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $3.11 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $13.49 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $13.49 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $0.91 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $0.91 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $1.32 10-K · filed 2022-03-22 | |||
| 2020-12-31 | $3.20 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $4.86 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |